Literature DB >> 21129327

Stabilized glucagon formulation for bihormonal pump use.

Solomon S Steiner1, Ming Li, Robert Hauser, Roderike Pohl.   

Abstract

BACKGROUND: A promising approach to treat diabetes is the development of an automated bihormonal pump administering glucagon and insulin. A physically and chemically stable glucagon formulation does not currently exist. Our goal is to develop a glucagon formulation that is stable as a clear ungelled solution, free of fibrils at a pH of 7 for at least 7 days at 37 °C.
METHODS: Experimental glucagon formulations were studied for stability at 25 and 37 °C. Chemical degradation was quantified by reverse phase ultra-performance liquid chromatography. Physical changes were studied using light obscuration and visual observations.
RESULTS: Glucagon content of Biodel glucagon and Lilly glucagon at pH 2 and pH 4, as measured by high-performance liquid chromatography at 25 °C, was 100% at 7 days compared to 87% and <7%, respectively. Light obscuration measurements indicated Lilly glucagon at pH 4 formed an opaque gel, while Biodel glucagon formulation remained a clear solution beyond 50 days at 37 °C. Visual observations confirmed these results.
CONCLUSIONS: Biodel glucagon is a stabilized formulation at physiological pH and remains chemically and physically stable beyond 7 days at 37 °C, suggesting its utility for use in a bihormonal pump.
© 2010 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129327      PMCID: PMC3005042          DOI: 10.1177/193229681000400606

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  23 in total

1.  The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting.

Authors:  Jesper Søndergaard Pedersen; Dantcho Dikov; James L Flink; Hans Aage Hjuler; Gunna Christiansen; Daniel Erik Otzen
Journal:  J Mol Biol       Date:  2005-11-09       Impact factor: 5.469

2.  A closed-loop artificial pancreas using model predictive control and a sliding meal size estimator.

Authors:  Hyunjin Lee; Bruce A Buckingham; Darrell M Wilson; B Wayne Bequette
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

3.  FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus.

Authors:  Arleen Pinkos; Guillermo Arreaza-Rubin; William J Heetderks; Ilan Irony; Hylton V Joffe; Bruce Schneider; Charles L Zimliki
Journal:  Drug Discov Today Technol       Date:  2007

4.  Formation and structure of gels and fibrils from glucagon.

Authors:  G H Beaven; W B Gratzer; H G Davies
Journal:  Eur J Biochem       Date:  1969-11

5.  A bihormonal closed-loop artificial pancreas for type 1 diabetes.

Authors:  Firas H El-Khatib; Steven J Russell; David M Nathan; Robert G Sutherlin; Edward R Damiano
Journal:  Sci Transl Med       Date:  2010-04-14       Impact factor: 17.956

6.  Insulin patch pumps: their development and future in closed-loop systems.

Authors:  Henry Anhalt; Nancy J V Bohannon
Journal:  Diabetes Technol Ther       Date:  2010-06       Impact factor: 6.118

7.  Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events.

Authors:  Benyamin Grosman; Eyal Dassau; Howard C Zisser; Lois Jovanovic; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

8.  Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor.

Authors:  Richard Mauseth; Youqing Wang; Eyal Dassau; Robert Kircher; Donald Matheson; Howard Zisser; Lois Jovanovic; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2010-07-01

Review 9.  Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.

Authors:  Vasiliki Valla
Journal:  Exp Diabetes Res       Date:  2010-05-26

10.  Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils.

Authors:  Satomi Onoue; Keiichi Ohshima; Kazuhiro Debari; Keitatsu Koh; Seiji Shioda; Sumiko Iwasa; Kazuhisa Kashimoto; Takehiko Yajima
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more
  20 in total

Review 1.  Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Authors:  Melanie A Jackson; Nicholas Caputo; Jessica R Castle; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Curr Diab Rep       Date:  2012-12       Impact factor: 4.810

2.  Mechanisms of glucagon degradation at alkaline pH.

Authors:  Nicholas Caputo; Jessica R Castle; Colin P Bergstrom; Julie M Carroll; Parkash A Bakhtiani; Melanie A Jackson; Charles T Roberts; Larry L David; W Kenneth Ward
Journal:  Peptides       Date:  2013-05-04       Impact factor: 3.750

3.  Biochemical stabilization of glucagon at alkaline pH.

Authors:  Nicholas Caputo; Melanie A Jackson; Jessica R Castle; Joseph El Youssef; Parkash A Bakhtiani; Colin P Bergstrom; Julie M Carroll; Matthew E Breen; Gerald L Leonard; Larry L David; Charles T Roberts; W Kenneth Ward
Journal:  Diabetes Technol Ther       Date:  2014-06-26       Impact factor: 6.118

4.  Stability of Commercially Available Glucagon Formulation for Dual-Hormone Artificial Pancreas Clinical Use.

Authors:  Nadine Taleb; Adèle Coriati; Christian Khazzaka; Jonathan Bayonne; Virginie Messier; Rémi Rabasa-Lhoret
Journal:  Diabetes Technol Ther       Date:  2017-08-28       Impact factor: 6.118

5.  Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.

Authors:  Steven J Russell; Firas H El-Khatib; David M Nathan; Edward R Damiano
Journal:  J Diabetes Sci Technol       Date:  2010-11-01

6.  The Use of Surfactants to Solubilise a Glucagon Analogue.

Authors:  Jens Kvist Madsen; Lise Giehm; Daniel E Otzen
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

7.  Dual self-regulated delivery of insulin and glucagon by a hybrid patch.

Authors:  Zejun Wang; Jinqiang Wang; Hongjun Li; Jicheng Yu; Guojun Chen; Anna R Kahkoska; Valerie Wu; Yi Zeng; Di Wen; Jayson R Miedema; John B Buse; Zhen Gu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-11       Impact factor: 11.205

8.  Hypoglycemia Detection and Carbohydrate Suggestion in an Artificial Pancreas.

Authors:  Kamuran Turksoy; Jennifer Kilkus; Iman Hajizadeh; Sediqeh Samadi; Jianyuan Feng; Mert Sevil; Caterina Lazaro; Nicole Frantz; Elizabeth Littlejohn; Ali Cinar
Journal:  J Diabetes Sci Technol       Date:  2016-11-01

9.  Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.

Authors:  Ahmad Haidar; Laurent Legault; Maryse Dallaire; Ammar Alkhateeb; Adèle Coriati; Virginie Messier; Peiyao Cheng; Maude Millette; Benoit Boulet; Rémi Rabasa-Lhoret
Journal:  CMAJ       Date:  2013-01-28       Impact factor: 8.262

Review 10.  Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia.

Authors:  Colin P Hawkes; Diva D De Leon; Michael R Rickels
Journal:  Curr Diab Rep       Date:  2019-09-06       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.